Treatment sequencing and the benefits of DMTs episode artwork

EPISODE · Jun 30, 2022 · 40 MIN

Treatment sequencing and the benefits of DMTs

from touchPODCAST · host touchpodcast

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading multiple sclerosis (MS) experts discuss their perspectives on the benefits of disease-modifying therapies (DMTs) in MS, and current approaches to treatment sequencing.  The experts Prof. Gavin Giovannoni (Chair), Blizard Institute, Queen Mary University of London, UK Prof. Eva Havrdová, General Faculty Hospital, Charles University in Prague, Czech Republic Prof. Patrick Vermersch, Lille University Hospital, France This touchPODCAST is for HCPs only.  This activity is funded by an unrestricted independent educational grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchneurology.com/cme/treatment-sequencing-in-ms-the-benefits-of-dmts/   

Episode metadata supplied by the publisher feed · Published Jun 30, 2022

Embed this episode

Ready to play

Treatment sequencing and the benefits of DMTs

0:00 40:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 40 minutes long.

When was this touchPODCAST episode published?

This episode was published on June 30, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!